Targeting dendritic cells in situ for breast cancer immunotherapy

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1398-1400

  Wang, Bei ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Breast cancer; DEC205; Dendritic cell targeting; HER2; Protein vaccine

Indexed keywords

CANCER VACCINE; GAG PROTEIN; TOLL LIKE RECEPTOR; TRASTUZUMAB; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; TARGET CELL; TUMOR IMMUNITY;

EID: 84886944430     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20982     Document Type: Note

References (9)

1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656.
2. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173.
3. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375:151-5; PMID:7753172; http://dx.doi.org/10.1038/375151a0.
4. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 2012; 271:183-92; PMID:22126373; http://dx.doi.org/10.1111/j.1365-2796.2011.02496.x.
5. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012; 14:39; PMID:22397502; http://dx.doi.org/10.1186/bcr3135.
6. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 2009; 21:185-93; PMID:19502082; http://dx.doi. org/10.1016/j.smim.2009.05.005.
7. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206:1589-602; PMID:19564349; http://dx.doi.org/10.1084/jem.20090247.
8. Hemmi H, Idoyaga J, Suda K, Suda N, Kennedy K, Noda M, et al. A new triggering receptor expressed on myeloid cells (Trem) family member, Trem-like 4, binds to dead cells and is a DNAX activation protein 12-linked marker for subsets of mouse macrophages and dendritic cells. J Immunol 2009; 182:1278-86; PMID:19155473.
9. Hemmi H, Zaidi N, Wang B, Matos I, Fiorese C, Lubkin A, et al. Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein. J Immunol 2012; 188:1147-55; PMID:22210914; http://dx.doi.org/10.4049/jimmunol.1102541.